Lit­tle Pro­teon shares crash in­to pen­ny stock ter­ri­to­ry as lead drug flops in PhI­II

Lit­tle Pro­teon Ther­a­peu­tics took a tor­pe­do right at the wa­ter line this morn­ing, re­port­ing that its Phase III study of von­a­pan­i­tase for chron­ic kid­ney dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER